Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. Show more
Location: 275 Shoreline Drive, Redwood City, CA, 94065, United States | Website: https://www.rezolutebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
800M
52 Wk Range
$2.21 - $9.72
Previous Close
$8.81
Open
$8.90
Volume
1,013,621
Day Range
$8.72 - $9.16
Enterprise Value
668.3M
Cash
167.9M
Avg Qtr Burn
-17.27M
Insider Ownership
9.26%
Institutional Own.
92.12%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ersodetug Details Tumor Hyperinsulinism (Tumor HI) | Phase 3 Data readout | |
Phase 3 Data readout |